X4 Pharmaceuticals, Inc.XFORNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank59
3Y CAGR-41.9%
5Y CAGR-3.3%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-41.9%/yr
Quarterly compound
5Y CAGR
-3.3%/yr
Recent deceleration
Percentile
P59
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 6.83% |
| Q3 2025 | -5.53% |
| Q2 2025 | -0.87% |
| Q1 2025 | -14.69% |
| Q4 2024 | 13.19% |
| Q3 2024 | -8.32% |
| Q2 2024 | 5.67% |
| Q1 2024 | 29.60% |
| Q4 2023 | -19.96% |
| Q3 2023 | 22.31% |
| Q2 2023 | -29.29% |
| Q1 2023 | 16.04% |
| Q4 2022 | 34.76% |
| Q3 2022 | 2.09% |
| Q2 2022 | -2.07% |
| Q1 2022 | 16.04% |
| Q4 2021 | -7.78% |
| Q3 2021 | -0.04% |
| Q2 2021 | 9.00% |
| Q1 2021 | -1.58% |
| Q4 2020 | 8.06% |
| Q3 2020 | 21.83% |
| Q2 2020 | 4.84% |
| Q1 2020 | 26.13% |
| Q4 2019 | -17.74% |
| Q3 2019 | -2.99% |
| Q2 2019 | 56.57% |
| Q1 2019 | 30.18% |
| Q4 2018 | -54.62% |
| Q3 2018 | 7.19% |
| Q2 2018 | 9.80% |
| Q1 2018 | -11.89% |
| Q4 2017 | -12.93% |
| Q3 2017 | 171.40% |
| Q2 2017 | -11.05% |
| Q1 2017 | 3.88% |
| Q4 2016 | 0.00% |
| Q1 2016 | 0.00% |